Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology CoROCO:4728 +1.06%91 EV-to-FCF is 25.99 as of Jul. 13, 2026, which is 18% above its 10-year median of 21.98. GuruFocus rates ROCO:4728 with a GF Score™ of 91/100 and a GF Value™ of NT$441.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 329 Biotechnology companies, Sunmax Biotechnology Co ranks worse than 61.7% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sunmax Biotechnology Co's Enterprise Value is NT$19,690 Mil.
Sunmax Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$758 Mil. Therefore, Sunmax Biotechnology Co's EV-to-FCF for today is 25.99.
The historical rank and industry rank for Sunmax Biotechnology Co's EV-to-FCF or its related term are showing as below:
ROCO:4728'
s EV-to-FCF Range Over the Past 10 Years
Min: -1410.05 Med: 21.98 Max: 157.15
Current: 25.99
During the past 13 years, the highest EV-to-FCF of Sunmax Biotechnology Co was 157.15. The lowest was -1410.05. And the median was 21.98.
ROCO:4728's EV-to-FCF is ranked worse than 61.7% of 329
companies
in the Biotechnology industry
Industry Median: 15.61
vs ROCO:4728: 25.99
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunmax Biotechnology Co (ROCO:4728) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunmax Biotechnology Co's PE Ratio (TTM) for today is calculated as:
Sunmax Biotechnology Co's share price for today is NT$381.00.
Sunmax Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$13.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4728 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Sunmax Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's EV-to-FCF falls into.
Sunmax Biotechnology Co's current Enterprise Value is NT$19,690 Mil.
Sunmax Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$758 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunmax Biotechnology Co (ROCO:4728) has a EV-to-FCF of 25.99 as of Jul. 13, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sunmax Biotechnology Co and its competitors. This is 18% above median its historical median of 21.98. According to the industry distribution chart, Sunmax Biotechnology Co ranks #203 out of 329 companies in the Biotechnology industry, placing it in the top 61.7%.
Is Sunmax Biotechnology Co's EV-to-FCF too high?
Sunmax Biotechnology Co's current EV-to-FCF of 25.99 is 18% above median its 10-year median of 21.98. The Biotechnology industry median EV-to-FCF is 15.61. Sunmax Biotechnology Co's value of 25.99 is 66.5% above this industry median. Based on the distribution chart, Sunmax Biotechnology Co ranks #203 out of 329 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunmax Biotechnology Co ranks #203 out of 329 companies for EV-to-FCF. This places Sunmax Biotechnology Co in the lower half of its industry. The industry median EV-to-FCF is 15.61. Sunmax Biotechnology Co's value of 25.99 is 66.5% above this benchmark. While the company's 10-year median is 21.98 vs. the industry median of 15.61, Sunmax Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.61, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunmax Biotechnology Co's current EV-to-FCF of 25.99 is 66.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sunmax Biotechnology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunmax Biotechnology Co's current EV-to-FCF is 25.99, which is 18% above median its own 10-year median of 21.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$441.22, compared to a current price of NT$381.00 — trading 13.6% below its estimated fair value. The current EV-to-FCF is 25.99, which is 18% above median its 10-year median of 21.98 and 66.5% above the Biotechnology industry median of 15.61. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current EV-to-FCF is 25.99 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued.
The current stock price of NT$381.00 is trading 13.6% below its estimated GF Value™ of NT$441.22.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Undervalued.
Key valuation signals for ROCO:4728:
EV-to-FCF: 25.99 (18% above median its 10-year median of 21.98)
GF Value™: NT$441.22 vs. price of NT$381.00 (13.6% below fair value)
Industry Position: 66.5% above the Biotechnology median (#203 of 329)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score
Get the complete analysis for ROCO:4728
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
